Although some guidelines recommend testing for aCL IgA, aß2GP1 IgA, aPS/PT IgG, and IgM in patients with a high suspicion of APS and who are negative for criteria antibodies, their incorporation into routine clinical practice has not been validated due to the lack of performance and standardization [22]. This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.